Polyclonal · Monoclonal · Recombinant
Hybridoma & Phage Display
Full Characterization
Conjugation Services
GMP-Grade Available
Service Overview
End-to-End Antibody Development, From Antigen to Application
ICDMO's antibody development platform integrates immunology expertise, advanced hybridoma technology, phage display, and recombinant expression to deliver custom antibodies of exceptional quality. Whether your goal is a research-grade polyclonal serum, a hybridoma-derived monoclonal for diagnostic standardization, or a sequence-defined recombinant IgG for therapeutic development, our team manages every step from antigen design through application validation.
Every antibody project is supported by rigorous titer monitoring, specificity confirmation, and application-specific validation. We offer optional epitope mapping, affinity measurement (SPR/BLI), isotype determination, and conjugation services to deliver a fully characterized antibody ready for your intended use.
500+
Antibodies Developed
10+
Host Species
6+
Antibody Formats
Antibody Types
Three Core Antibody Platforms
Each platform is supported by dedicated scientists with deep immunology and protein engineering expertise.
What We Offer
Immunization & Antigen Preparation
▸Recombinant protein, peptide conjugate (KLH/BSA), DNA, cell, and VLP antigens accepted
▸Custom antigen design and production service available if required
▸Multi-species immunization: rabbit, mouse, rat, goat, sheep, guinea pig, chicken
▸Adjuvant selection (CFA/IFA, TiterMax, Freund's) optimized per antigen type
▸Immunization schedule design: 3-injection or 4-injection protocol with titer monitoring by ELISA
Hybridoma Development & Screening
▸Spleen fusion with SP2/0 or P3X63 myeloma cells using PEG or electrofusion
▸HAT selection and primary screening by ELISA within 3 weeks of fusion
▸Secondary screening: specificity (Western blot, IF, FC, IHC) and isotype determination
▸Subcloning by limiting dilution: minimum 2 rounds to ensure monoclonality
▸Stable hybridoma banking: cryopreservation of ≥5 vials per confirmed clone
Antibody Production & Purification
▸Ascites production (murine/rat) or roller bottle / bioreactor cell culture
▸Protein A/G affinity purification → dialysis into PBS or custom buffer
▸Optional: Fab / F(ab')₂ fragmentation by papain/pepsin digestion
▸IgG, IgM, IgA, IgY isotypes; subclass-specific secondary antibody available
▸Conjugation: HRP, biotin, FITC, PE, APC, Alexa Fluor dyes, quantum dots
Antibody Characterization
▸Titer determination by direct and indirect ELISA
▸Affinity measurement: KD by SPR (Biacore), BLI (Octet), or ELISA-based titration
▸Specificity panel: Western blot (denaturing / native), dot blot, immunoprecipitation
▸Application validation: IHC (FFPE & frozen), IF/ICC, flow cytometry, ELISA, ChIP
▸Epitope mapping: overlapping peptide ELISA, alanine scanning, hydrogen-deuterium exchange
Key Advantages
Broad Host Species
Rabbit, mouse, rat, goat, sheep, guinea pig, chicken, and llama for VHH nanobody development.
Established Hybridoma Route
Target number of antigen-positive clones per project is agreed in the statement of work, together with what happens if the campaign falls short.
Phage Display Option
Human or llama antibody libraries for generation of fully human or VHH antibodies without animal immunization.
Complete Characterization
Affinity (KD by SPR/BLI), epitope mapping, isotyping and multi-application validation, coordinated through qualified partner laboratories.
Conjugation Services
HRP, biotin, FITC, PE, APC, Alexa Fluor, quantum dot and custom conjugation, with lot-to-lot specifications agreed before work starts.
GMP-Grade Production
Therapeutic antibody production arranged through qualified GMP partners, with batch records and regulatory documentation supplied by the manufacturing site.
Development Workflow
1
Project Consultation & Antigen Review
Submit your antigen information (sequence, structure, target epitope, intended application). Our scientists assess immunogenicity and recommend immunization strategy and host species.
2
Antigen Preparation
Recombinant protein expression or peptide synthesis. Peptides coupled to KLH/BSA carrier. QC by SDS-PAGE and endotoxin testing before immunization.
3
Animal Immunization & Titer Monitoring
Immunization in selected host species. Serum collected at defined intervals and titer verified by ELISA. Booster injections until target titer achieved (typically ≥1:10,000).
4
Hybridoma Fusion & Primary Screening (mAb only)
Spleen cell fusion, HAT selection, and ELISA primary screening of ~1,000 clones. Positive wells identified within 2–3 weeks of fusion.
5
Secondary Screening & Subcloning
Specificity confirmation by Western blot, IF, or FC. Two rounds of limiting dilution subcloning to ensure monoclonality. Isotype determination by lateral flow assay.
6
Antibody Production, Purification & QC
Scale-up in bioreactor or ascites. Protein A/G purification to >95% purity. Final QC: SDS-PAGE, Western blot, ELISA titer, endotoxin. CoA and sequence report delivered.
Service Process
1
Project Consultation
›
2
Antigen Preparation
›
3
Immunization
›
4
Screening & Cloning
›
5
Production & QC
Specifications & Timeline
Note: All timelines are estimates for standard projects. Complex antigens or low-immunogenicity targets may require additional immunization rounds. For GMP-grade therapeutic antibody production, please contact us for a customized development plan.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
10- to 140-fold affinity improvements from computational design
Computational interface redesign produced a tenfold affinity improvement in cetuximab, reaching 52 pM, and a 140-fold improvement to 30 pM for an anti-lysozyme model antibody — improvements achieved by designing a small number of interface substitutions rather than by library selection.
Lippow, Wittrup & Tidor, Nature Biotechnology, 2007 ↗Interface models predict which substitutions help, with measurable accuracy
A 2024 study combining structural interface analysis with sequence-derived evolutionary information reported a predictive model for antibody–antigen interaction with an area under the curve of 0.83 and precision of 0.89 on held-out data, and experimentally confirmed a designed point mutation that improved affinity 2.5-fold to 2 nM. Typical computational maturation gains are modest per mutation, which is why a designed panel is measured rather than a single variant.
Experimental validation study, 2024 ↗What We Need From You
▸Antigen sequence (FASTA) with species, isoform and the construct boundaries you intend to use
▸Antigen structure or a related family structure where one exists, including unpublished internal coordinates
▸The epitope or region you want antibodies against, and any region that must be avoided
▸Intended application — therapeutic, diagnostic, reagent, imaging — since it sets the developability bar
▸Any existing binders, immunisation history or previous campaigns, including what failed and why
How the Work Is Performed
▸Antigen analysis: domain architecture, glycosylation, disorder, conservation and surface accessibility
▸Epitope assessment and immunogenicity prediction to guide immunogen design and region selection
▸Immunogen construct design, including fragment boundaries, fusion partners and carrier coupling strategy
▸Structural modelling of the antigen and, once binders exist, of the antibody–antigen complex
▸Sequence triage of hybridoma or display output: germline assignment, clustering and liability screening
▸Developability assessment across the candidate panel before expression resource is committed
What You Receive
▸Immunogen design recommendation with the reasoning and the alternatives considered
▸Antigen and epitope analysis with annotated structural figures
▸Candidate sequence triage: clustered families, germline assignment and ranked developability
▸Structural models of the leading candidates, with complex models where the epitope is known
▸A prioritised expression and characterisation plan stating what each candidate tests
Interpretation and Limitations
Computational antigen and epitope analysis improves the odds of a campaign; it does not determine whether an animal or a library will yield binders. Immunogenicity prediction is indicative rather than decisive, and developability scores flag risk rather than establish outcome. Immunisation, expression and binding characterisation are executed by qualified partner laboratories and scoped separately from the computational work.
Questions We Are Asked Before Scoping
Do you run the immunisation and screening yourselves?
No. ICDMO is a computational CDMO. We design the immunogen and the strategy, triage the resulting sequences and model the candidates; the laboratory work is carried out by qualified partners and coordinated with you.
Can you help if a previous campaign failed?
Frequently, yes. Failures often trace to immunogen design, an epitope that is glycosylated or disordered, or a conserved target with poor immunogenicity. We analyse the antigen and say what we would change before the next attempt.
What can you tell us before any antibody exists?
Which regions are accessible and likely immunogenic, which construct boundaries are sensible, where tolerance is likely to be a problem, and which format suits the intended application. That is usually enough to design a better campaign.
Get a Custom Quote
Antibody scientists respond within 24 hours with a tailored development plan and pricing.
Contact Us Online ConsultationStandard Deliverables
✓Purified antibody (specified qty)
✓ELISA titer report
✓SDS-PAGE under reducing conditions
✓Western blot validation
✓Isotype determination
✓Certificate of Analysis (CoA)
✓Stable hybridoma vials (mAb projects)
Why ICDMO?
Computational Design & Triage
Sequence and Structure Assessment
Hybridoma + Phage Display Routes
Characterisation Through Partners
GMP Through Qualified Partners